The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1–based chemoradiotherapy in advanced gastric cancer.
H. Shim
No relevant relationships to disclose
W. K. Bae
No relevant relationships to disclose
J. Hwang
No relevant relationships to disclose
J. Yoon
No relevant relationships to disclose
D. H. Yang
No relevant relationships to disclose
T. Nam
No relevant relationships to disclose
S. Ryu
No relevant relationships to disclose
Y. Park
No relevant relationships to disclose
I. Chung
No relevant relationships to disclose